Clinical Use Patterns and Patient-Reported Experience with Inhaled Levodopa in Routine Practice: A Two-Center Study
Medical Sciences · 28.07.2026 · 14 (4) · 446
DOI: 10.3390/medsci14040446 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Medical Sciences, online erschienen am 28.07.2026. Verfasst von Tania Delgado Ballestero und 2 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Consorci Corporació Sanitària Parc Taulí, Hospital Universitari Parc Taulí, 08208 Sabadell, Spain. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease, Antiparkinson Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Esteve (Spain).
Abstract (Originalsprache)
Background/Objectives: On-demand therapies are crucial to manage OFF episodes in Parkinson’s disease (PD). Inhaled levodopa is a rapid and non-invasive treatment option, but data on its real-world use and patient-reported experience remain limited. This study characterized clinical use patterns and patient experience with inhaled levodopa in routine clinical practice.
Methods
We conducted a multicenter, cross-sectional, observational study including patients with PD treated with inhaled levodopa in two Spanish centers. Data on treatment use, patient-reported clinical response, and satisfaction were collected during a single study visit using study-specific questionnaires.
Results
Thirty-five patients were included (mean age 70.6 years; 51.4% women). Most patients used inhaled levodopa once daily (51.4%), with administration patterns varying between on-demand (51.4%), fixed (31.4%), and combined regimens (17.1%). According to routine clinical assessments, 80.0% of patients reported a clinical response to inhaled levodopa, with a mean time to onset of 17.7 min and a mean duration of effect of 122.1 min. The perceived response was rated as moderate or marked in 62.8% of patients and was reported to last until the next scheduled oral levodopa dose in 45.7% of patients. Participants highlighted symptom improvement, ease of identifying the appropriate timing of administration, and a favorable perception of treatment safety.
Conclusions
In routine clinical practice, inhaled levodopa was associated with a high patient-reported clinical response and favorable treatment experience across diverse patient profiles. These findings provide relevant insights into the real-world use of inhaled levodopa as an on-demand therapy for OFF episodes in PD. Given the exploratory nature of this study, confirmation in larger prospective studies using validated instruments and objective clinical measures is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Department, Consorci Corporació Sanitària Parc Taulí, Hospital Universitari Parc Taulí, 08208 Sabadell, Spain.
- Neurology Department, Hospital Universitari de Tortosa Verge de la Cinta, Institut Català de la Salut, 43500 Tortosa, Spain.
- Institut d'Investigació Sanitària Pere Virgili (IISPV), 43005 Tarragona, Spain.
ORCID-Profile: Tania Delgado Ballestero, Sonia Escalante Arroyo
Förderung
- Esteve (Spain)
Zitieren
APA
Delgado Ballestero, T., Escalante Arroyo, S., & Mandrá Noya, M. A. (2026). Clinical Use Patterns and Patient-Reported Experience with Inhaled Levodopa in Routine Practice: A Two-Center Study. Medical Sciences, 14(4), 446. https://doi.org/10.3390/medsci14040446
Vancouver
Delgado Ballestero T, Escalante Arroyo S, Mandrá Noya MA. Clinical Use Patterns and Patient-Reported Experience with Inhaled Levodopa in Routine Practice: A Two-Center Study. Medical Sciences. 2026;14(4):446. doi:10.3390/medsci14040446
BibTeX
@article{DelgadoBallestero2026,
author = {Delgado Ballestero, Tania and Escalante Arroyo, Sonia and Mandrá Noya, Marcos Alfredo},
title = {Clinical Use Patterns and Patient-Reported Experience with Inhaled Levodopa in Routine Practice: A Two-Center Study},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {4},
pages = {446},
doi = {10.3390/medsci14040446}
}
EUVIMED